Edition:
United States

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

2.20USD
20 Jan 2017
Change (% chg)

$-0.05 (-2.22%)
Prev Close
$2.25
Open
$2.25
Day's High
$2.25
Day's Low
$2.19
Volume
152,691
Avg. Vol
274,404
52-wk High
$4.37
52-wk Low
$1.89

RIGL.OQ

Chart for RIGL.OQ

About

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. The Company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in... (more)

Overall

Beta: 1.25
Market Cap(Mil.): $217.66
Shares Outstanding(Mil.): 98.94
Dividend: --
Yield (%): --

Financials

  RIGL.OQ Industry Sector
P/E (TTM): -- 44.85 30.38
EPS (TTM): -0.72 -- --
ROI: -76.96 -1.38 14.86
ROE: -81.69 -1.07 16.28

BRIEF-Rigel announces third quarter 2016 financial results

* Rigel announces third quarter 2016 financial results and provides company update

Nov 01 2016

Rigel's bleeding disorder drug fails late-stage study

Rigel Pharmaceuticals Inc said its lead drug to treat a bleeding disorder failed in a second late-stage trial, sending its shares tumbling 32 percent in premarket trading on Thursday.

Oct 20 2016

UPDATE 1-Rigel's bleeding disorder drug fails late-stage study

Oct 20 Rigel Pharmaceuticals Inc said its lead drug to treat a bleeding disorder failed in a second late-stage trial, sending its shares tumbling 32 percent in premarket trading on Thursday.

Oct 20 2016

Rigel's bleeding disorder drug fails late-stage study

Oct 20 Rigel Pharmaceuticals Inc said its bleeding disorder drug failed in a late-stage study, sending its shares down 37 percent in premarket trading on Thursday.

Oct 20 2016

BRIEF-Rigel's fostamatinib fails late-stage study

* Rigel announces results from the second fit phase 3 study and the long-term open-label extension study for fostamatinib in itp

Oct 20 2016

BRIEF-Rigel Pharmaceuticals expects to file an investigational new drug application (IND) with FDA for its first IRAK inhibitor in 2017

* Expects to file an investigational new drug application (IND) with FDA for its first IRAK inhibitor in 2017 Source text for Eikon: Further company coverage:

Oct 07 2016

BRIEF-Rigel Pharma expects to complete workforce reduction by Dec 15

* Says expects to complete workforce reduction by December 15, 2016 - SEC filing Source text: [http://bit.ly/2cQgmHf] Further company coverage:

Sep 15 2016

BRIEF-Rigel restructures to focus on Fostamatinib commercialization

* Rigel restructures to focus on fostamatinib commercialization

Sep 15 2016

Rigel's bleeding disorder drug clears first of two key trials

Rigel Pharmaceuticals Inc said its experimental drug to treat a bleeding disorder met its main goal in the first of two late-stage trials, sending its shares up 12 pct in premarket trade.

Aug 30 2016

UPDATE 1-Rigel's bleeding disorder drug clears first of two key trials

Aug 30 Rigel Pharmaceuticals Inc said its experimental drug to treat a bleeding disorder met its main goal in the first of two late-stage trials, sending its shares up 12 pct in premarket trade.

Aug 30 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF70.90 -0.20
Roche Holding Ltd. (ROG.S) CHF233.50 +0.50
Roche Holding Ltd. (RO.S) CHF236.10 +0.10
Merck & Co., Inc. (MRK.N) $62.53 +2.20
Sanofi SA (SASY.PA) €75.62 -0.15
AstraZeneca plc (AZN.L) 4,318.50 -150.00
Abbott Laboratories (ABT.N) $40.46 +0.06

Earnings vs. Estimates